Dr. Bishop has over 20 years of experience in drug development and research, having led the department of novel therapeutics in a variety of neurological and rare genetic disease areas. She has experience leading preclinical as well as clinical development from IND filings through Phase 3 registration-enabling studies. Currently, Dr. Bishop is the Chief Scientific Officer of Otonomy Inc. Prior to that, Dr. Bishop was Chief Science Officer at Locana Bio. Prior to her current appointment Dr. Bishop served as CSO at Tioga Pharmaceuticals, and Vice President of Clinical Development at Ionis Pharmaceuticals, where she provided drug development leadership to a portfolio of programs within the neurology franchise and led clinical stage development programs in Spinal Muscular Atrophy, Myotonic Dystrophy and Amyotrophic Lateral Sclerosis. Dr. Bishop was also Director of Research and Development at Ceregine, Inc., where she led the preclinical development of viral-vector based therapeutics for degenerative diseases including Alzheimer's, Huntington's, Parkinson's, ALS and retinal degenerative diseases. Dr. Bishop also has extensive experience in successfully partnering programs with pharmaceutical companies. She received her PhD in neuroscience from the University of Alberta, Canada, and conducted post-doctoral fellowship work at the Salk Institute in La Jolla, California, in molecular neurobiology.